A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the ...

Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to ...

The tech trade is proving resilient, even unstoppable, while the firms that gained by helping people lose weight are ...

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who used semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).

In light of the exploding popularity of GLP-1 medications like Ozempic and Wegovy, U.S. Anesthesia Partners, Inc. (USAP) is encouraging all patients taking GLP-1 receptor medication to consult with ...

The biotech company extends its Phase I trial (NCT06252220) of DA-1726 to eight weeks following encouraging early efficacy, ...

No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA versus DPP4i users.

For older adults with type 2 diabetes, GLP-1 RA use is associated with nonarteritic anterior ischemic optic neuropathy.

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...